Scarica l'app Stockscreener
4.85
0.62%
0.03
Dopo l'orario di chiusura:
4.86
0.01
+0.21%
Precedente Chiudi:
$4.82
Aprire:
$4.83
Volume 24 ore:
455.32K
Relative Volume:
0.72
Capitalizzazione di mercato:
$282.79M
Reddito:
$192.64M
Utile/perdita netta:
$2.51M
Rapporto P/E:
92.56
EPS:
0.0524
Flusso di cassa netto:
$12.42M
1 W Prestazione:
+0.83%
1M Prestazione:
-1.22%
6M Prestazione:
-9.51%
1 anno Prestazione:
+13.32%
Intervallo 1D:
$4.79
$4.9038
Intervallo di 1 settimana:
$4.7105
$4.955
Portata 52W:
$3.46
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Confronta VNDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.85 | 282.79M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
Vanda’s VGT-1849A gets orphan designation for polycythemia vera - BioWorld Online
HC Wainwright Reiterates Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity - Seeking Alpha
Vanda Pharmaceuticals Gets FDA Orphan-Drug Designation for Cancer Treatment - MarketWatch
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
Vanda Pharmaceuticals Secures FDA Orphan Drug Status for Novel Blood Cancer Treatment VGT-1849A - StockTitan
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com - MarketBeat
FDA's Gastro Drug Fast-Track Denial Survives DC Circ. - Law360
US Penny Stocks To Watch In December 2024 - Simply Wall St
DC Circuit Affirms FDA's Fast-Track Denial of Vanda Stomach Drug - Bloomberg Law
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc. - Marketscreener.com
Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com
Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
Vanda Expands Efforts to Pull Two Hetlioz Copies From US Shelves - Bloomberg Law
Vanda Pharmaceuticals (STU:VM4) EV-to-Revenue : -0.37 (As of Dec. 01, 2024) - GuruFocus.com
Massachusetts Financial Services Co. MA Purchases New Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Long Term Trading Analysis for (VNDA) - Stock Traders Daily
Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com Canada
Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India
New Strong Buy Stocks For November 14th - Barchart
Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan
BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Inc (VNDA) Quarterly 10-Q Report - Quartz
Vanda Seeks New Markets for Hetlioz Amid Generic Competition - Sleep Review
Vanda: Q3 Earnings Snapshot - Middletown Press
Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... - Yahoo Finance
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results - PR Newswire
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):